Skip to main content

Laura Jean Havrilesky, MD

Laura Havirlesky, MD
Professor of Obstetrics and Gynecology
Campus Mail: 25172 Morris Bldg, Durham, NC 27710
Phone: (919) 684-0188
Email: havri001@mc.duke.edu

I am interested in using health economic models to inform decisions related to gynecologic cancers. Specific models have addressed the decision to administer intraperitoneal chemotherapy for newly diagnosed advanced ovarian cancer following optimal cytoreduction, the choice of chemotherapy regimen for recurrent platinum-sensitive ovarian cancer, and the exploration of screening strategies for ovarian cancer. The ovarian cancer screening model examines the effects of test cost, sensitivity, specificity, and screen frequency on ovarian cancer mortality, the lifetime false positive rate of testing, the positive predictive value of the test, and its cost effectiveness. This type of model is potentially useful in informing the design trials of novel screening tests for ovarian cancer. I am also conducting a prospective study to quantify the effects of screening for, diagnosis of, and treatment for ovarian cancer on the quality of life of women.

Education and Training

  • Residency, Obstetrics And Gynecology, Duke University, 1995 - 1999
  • M.D., Duke University, 1995

Research

I am interested in using health economic models to inform decisions related to gynecologic cancers. Specific models have addressed the decision to administer intraperitoneal chemotherapy for newly diagnosed advanced ovarian cancer following optimal cytoreduction, the choice of chemotherapy regimen for recurrent platinum-sensitive ovarian cancer, and the exploration of screening strategies for ovarian cancer.

The ovarian cancer screening model examines the effects of test cost, sensitivity, specificity, and screen frequency on ovarian cancer mortality, the lifetime false positive rate of testing, the positive predictive value of the test, and its cost effectiveness. This type of model is potentially useful in informing the design trials of novel screening tests for ovarian cancer. I am also conducting a prospective study to quantify the effects of screening for, diagnosis of, and treatment for ovarian cancer on the quality of life of women. 

Publications

Hong, JC, Spiegel, DY, Havrilesky, LJ, and Chino, JP. "High-volume providers and brachytherapy practice: A Medicare provider utilization and payment analysis." Brachytherapy 17, no. 6 (November 2018): 906-911.

Full Text

Spiegel, DY, Chino, F, Moss, H, Havrilesky, LJ, and Chino, JP. "Changes in insurance coverage for cancer patients receiving brachytherapy before and after enactment of the Affordable Care Act.(Published online)" Brachytherapy (October 20, 2018).

Full Text

Salinaro, JR, Puechl, AM, Havrilesky, LJ, and Davidson, BA. "Gender trends in gynecologic oncology authorship: Implications for the critical evaluation of gender distribution in academic rank and leadership positions." Gynecologic Oncology (October 9, 2018).

Full Text

Lim, SL, Moss, HA, Secord, AA, Lee, PS, Havrilesky, LJ, and Davidson, BA. "Hysterectomy with sentinel lymph node biopsy in the setting of pre-operative diagnosis of endometrial intraepithelial neoplasia: A cost-effectiveness analysis." Gynecologic Oncology (September 23, 2018).

Full Text

Fader, AN, Roque, DM, Siegel, E, Buza, N, Hui, P, Abdelghany, O, Chambers, SK, Secord, AA, Havrilesky, L, O'Malley, DM, Backes, F, Nevadunsky, N, Edraki, B, Pikaart, D, Lowery, W, ElSahwi, KS, Celano, P, Bellone, S, Azodi, M, Litkouhi, B, Ratner, E, Silasi, D-A, Schwartz, PE, and Santin, AD. "Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 36, no. 20 (July 2018): 2044-2051.

Full Text

Wright, JD, Havrilesky, LJ, Cohn, DE, Huang, Y, Rathbun, J, Rice, LW, Brown, CL, Alvarez, RD, and Ko, EM. "Estimating potential for savings for low risk endometrial cancer using the Endometrial Cancer Alternative Payment Model (ECAP): A companion paper to the Society of Gynecologic Oncology Report on the Endometrial Cancer Alternative Payment Model." Gynecologic Oncology 149, no. 2 (May 2018): 241-247.

Full Text

Chino, F, Suneja, G, Moss, H, Zafar, SY, Havrilesky, L, and Chino, J. "Health Care Disparities in Cancer Patients Receiving Radiation: Changes in Insurance Status After Medicaid Expansion Under the Affordable Care Act." May 2018.

Full Text

Davidson, BA, Ehrisman, J, Abbott, S, Harmon, Z, Secord, AA, Berchuck, A, Lee, PS, Valea, FA, Li, X, Havrilesky, LJ, and Hall, AHS. "Prospective Evaluation of Lymph Node Processing at Staging Surgery for High-grade Endometrial Cancer." International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists 37, no. 3 (May 2018): 252-255.

Full Text

Ko, EM, Havrilesky, LJ, Alvarez, RD, Zivanovic, O, Boyd, LR, Jewell, EL, Timmins, PF, Gibb, RS, Jhingran, A, Cohn, DE, Dowdy, SC, Powell, MA, Chalas, E, Huang, Y, Rathbun, J, and Wright, JD. "Society of Gynecologic Oncology Future of Physician Payment Reform Task Force report: The Endometrial Cancer Alternative Payment Model (ECAP)." Gynecologic Oncology 149, no. 2 (May 2018): 232-240.

Full Text

Moss, HA, Berchuck, A, Neely, ML, Myers, ER, and Havrilesky, LJ. "Estimating Cost-effectiveness of a Multimodal Ovarian Cancer Screening Program in the United States: Secondary Analysis of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)." Jama Oncology 4, no. 2 (February 2018): 190-195.

Full Text

Pages